Editas Medicine's science head Albright leaves for new job just as biotech gets trial clearance for sickle cell therapy
Editas Medicine has received the FDA’s blessing to enter the clinic with its first ex vivo cell therapy — but it will do so without CSO Charles Albright, who is leaving his post for the same gig at an early-stage company.
The FDA clearance was announced minutes after Editas shared word of Albright’s departure early Monday morning. The bittersweet news caused the biotech’s stock $EDIT to sink more than 12%, with shares hovering around $79 apiece.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.